Ursal, Kent B.
HRN: 22-41-36 Sex: MalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
01/06/2023
CEFTAZIDIME 1GM (VIAL)
01/06/2023
01/12/2023
IVT
115
Q8hrs
Neonatal Sepsis
Waiting Final Action
Indication: Empiric Type of Infection: Bloodstream Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes